Sacubitril/valsartan in COVID-19 patients: the need for trials

被引：11
|
作者：
Acanfora, Domenico [1 ]
Ciccone, Marco Matteo [2 ]
Scicchitano, Pietro [2 ,3 ]
Acanfora, Chiara [1 ,4 ]
Casucci, Gerardo [1 ]
机构：
[1] San Francesco Hosp, Unit Internal Med, Viale Europa 21, I-82037 Telese Terme, BN, Italy
[2] Univ Bari, Sch Med, Sect Cardiovasc Dis, Dept Emergency & Organ Transplantat, Bari, Italy
[3] Hosp F Perinei Altamura, Cardiol Unit, Bari, Italy
[4] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy
来源：
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2020年 / 6卷 / 04期
关键词：
D O I：
10.1093/ehjcvp/pvaa044
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：253 / 254
页数：2
相关论文
共 50 条
  • [1] Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy
    Rosano, Giuseppe M. C.
    Celant, Simone
    Olimpieri, Pier Paolo
    Colatrella, Antonietta
    Onder, Graziano
    Di Lenarda, Andrea
    Ambrosio, Giuseppe
    Reboldi, Gianpaolo
    Gensini, Gian Franco
    Colivicchi, Furio
    Russo, Pierluigi
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (05) : 855 - 860
  • [2] PREDICTORS OF LIKELIHOOD OF TAKING SACUBITRIL-VALSARTAN AND A HYPOTHETICAL MEDICATION FOR COVID-19
    Thomson, Mary Catherine
    Allen, Larry
    Halpern, Scott D.
    Ko, Yi-An
    Matlock, Daniel
    Moore, Miranda A.
    Morris, Alanna
    Rao, Birju
    Scherer, Laura D.
    Speight, Candace
    Ubel, Peter A.
    Dickert, Neal
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 560 - 560
  • [3] PP Influence of sacubitril/ valsartan on biochemical markers in patients with chronic heart failure after COVID-19
    Minovarova, C.
    Atadjanova, G.
    Uzokov, J.
    Tursunov, J.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54
  • [4] The need for COVID-19 clinical trials in LMICs
    Saleh, Fatima
    FRONTIERS IN PUBLIC HEALTH, 2023, 10
  • [5] Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID-19 infection: the PARACOR-19 randomized clinical trial
    Greene, Stephen
    Chambers, R.
    Lerman, J.
    Harrington, J.
    Defilippi, C. R.
    Green, C. L.
    Butler, J.
    Felker, G. M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 172 - 172
  • [6] Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID-19 infection: The PARACOR-19 randomized clinical trial
    Greene, Stephen J.
    Chambers, Rakavius
    Lerman, Joseph B.
    Harrington, Josephine
    deFilippi, Christopher R.
    Wendell, David C.
    Kim, Han W.
    Green, Cynthia L.
    Butler, Javed
    Felker, G. Michael
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (06) : 1393 - 1398
  • [7] Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19
    Vitiello, Antonio
    Porta, Raffaele La
    Ferrara, Francesco
    MEDICAL HYPOTHESES, 2021, 147
  • [8] Quality of life of patients with cardiomyopathy treated with sacubitril/ valsartan vs. standard therapy during or after COVID-19 in Kazakhstan
    Dadanbekova, Dana
    Zhakipbekov, Kairat
    Kodasbayev, Almat
    Datkhayev, Ubaidilla
    Petrova, Guenka
    Tachkov, Konstantin
    PHARMACIA, 2024, 71
  • [9] COVID-19: we need randomised trials of school closures
    Fretheim, Atle
    Flato, Martin
    Steens, Anneke
    Flottorp, Signe Agnes
    Rose, Christopher James
    Telle, Kjetil Elias
    Kinge, Jonas Minet
    Schwarze, Per Everhard
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2020, 74 (12) : 1078 - 1079
  • [10] Africa's need for more COVID-19 clinical trials
    Makoni, Munyaradzi
    LANCET, 2021, 397 (10289): : 2037 - 2037
12345